Ep 958 - WEIGHT LOSS DRUGS: GRAB YOURS FOR $50 EACH STARTING IN JULY!

A groundbreaking $50-per-drug program for Medicare beneficiaries is set to launch in July 2026, offering access to GLP-1 weight loss medications like Wagovi, ZipBound, and Foundio—only for those with qualifying health conditions. This 'Medicare GLP-1 Bridge' program, designed as a temporary fix while a broader policy rollout is delayed, will cover these drugs at a $50 copay for eligible participants enrolled in Part D plans, including Medicare Advantage. The initiative targets individuals with BMI 35+ or 30+ with serious comorbidities like heart failure, diabetes, or kidney disease. Despite the government's long-standing ban on covering weight loss drugs under Medicare, this demonstration program marks a significant shift, driven by rising obesity rates and the proven clinical benefits of GLP-1 therapies. However, the program is not a free pass—participants must commit to lifestyle changes and meet strict clinical criteria. Meanwhile, Doug Jones, host of the Medicare for the Lazy Man Podcast, continues his crusade against Medicare Advantage, warning of prior authorization delays and insurer gatekeeping, while also highlighting the growing financial strain on Medicare Supplement plans due to medical inflation, which has driven premium increases from 4.3% in 2022 to a projected 10.6% in 2025.